
Evolent Health (EVH) Stock Forecast & Price Target
Evolent Health (EVH) Analyst Ratings
Bulls say
Evolent Health Inc. exhibits a compelling growth trajectory, bolstered by its ability to cross-sell services and expand high-revenue contracts, notably forecasting potential growth from the Aetna contract to over $2 billion in annual revenue. The company reported strong top-line growth, exceeding its mid-teens revenue growth target, while maintaining a robust pipeline valued at $650 million, signaling significant market demand for its specialty-focused value-based care solutions. Evolent's strategic positioning leverages ongoing shifts in government programs towards value-based payment models, enhancing its prospects in the evolving healthcare landscape.
Bears say
The analysis of Evolent Health's financial outlook reveals significant concerns regarding projected revenue and EBITDA declines. The company anticipates a decrease in non-enhanced revenue from approximately $285 million in 2025 to $170 million in 2026, exacerbated by expected declines in Exchange and Medicare Advantage contracts. Additionally, potential drops in Medicaid membership and higher-margin Exchange enrollment could result in EBITDA reductions of $8 million to $15 million or more, reflecting a challenging environment for revenue stability and profitability.
This aggregate rating is based on analysts' research of Evolent Health and is not a guaranteed prediction by Public.com or investment advice.
Evolent Health (EVH) Analyst Forecast & Price Prediction
Start investing in Evolent Health (EVH)
Order type
Buy in
Order amount
Est. shares
0 shares